FRM
MDGL icon

Fox Run Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Fox Run Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
+418
New +$214K 0.04% 779
2025
Q4 		– Sell
-2,318
Closed -$1.06M – 1111
2025
Q3 		$1.06M Buy
+2,318
New +$865K 0.17% 184
2023
Q4 		– Sell
-2,835
Closed -$414K – 889
2023
Q3 		$414K Buy
+2,835
New +$534K 0.12% 327
2023
Q2 		– Sell
-1,138
Closed -$276K – 855
2023
Q1 		$276K Buy
+1,138
New +$310K 0.09% 429

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fox Run Management's MDGL Position: Q2 2026 in Review

Fox Run Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 418 shares worth $224K. The stake represents 0.04% of the portfolio and ranks #779 among its holdings. This is a return to the name: Fox Run Management previously reported a position in MDGL as recently as Q3 2025.

Fox Run Management first reported a position in MDGL in Q1 2023 and has held it in 4 quarters since. The position peaked at $1.06M in Q3 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Fox Run Management held 418 shares of Madrigal Pharmaceuticals worth $224K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Fox Run Management position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.04% of Fox Run Management's portfolio in Q2 2026, its #779 holding.
  • Fox Run Management first reported a position in Madrigal Pharmaceuticals in Q1 2023 and has held it in 4 quarters since.
  • Fox Run Management's Madrigal Pharmaceuticals position peaked at $1.06M in Q3 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.